Division of Pediatric Hematology/Oncology, Department of Pediatrics, Baystate Medical Center, Springfield, Massachusetts, USA.
Pediatrics. 2010 Apr;125(4):e938-50. doi: 10.1542/peds.2009-1597. Epub 2010 Mar 1.
Children treated for malignancies may be at risk for early- or delayed-onset hearing loss that can affect learning, communication, school performance, social interaction, and overall quality of life. Survivors at particular risk include those treated with platinum compounds (cisplatin and/or carboplatin) for neuroblastoma, hepatoblastoma, osteosarcoma, or germ-cell tumors and/or those treated with radiation that affects the ear at doses of >30 Gy for pediatric head and neck tumors. The aims of the Auditory/Hearing Late Effects Task Force of the Children's Oncology Group in this report were to (1) review ototoxicity resulting from childhood cancer therapy including platinum compounds (cisplatin and carboplatin) and radiation, (2) describe briefly cochlear pathophysiology and genetics of cisplatin-related hearing loss, (3) explain the impact of hearing loss resulting from chemotherapy and radiation, and (4) offer recommendations regarding evaluation and management of pediatric patients who are at risk for treatment-related hearing loss. A questionnaire is included as a tool to assist pediatricians in assessment.
接受恶性肿瘤治疗的儿童可能面临早发性或迟发性听力损失的风险，这可能会影响学习、沟通、学业表现、社交互动和整体生活质量。特别处于风险之中的是那些接受顺铂和/或卡铂治疗神经母细胞瘤、肝母细胞瘤、骨肉瘤或生殖细胞瘤的儿童，以及那些因接受剂量超过 30Gy 的耳照射而接受治疗的儿童，这些照射会影响头部和颈部的肿瘤。本儿童肿瘤学组听觉/听力迟发性不良效应工作组的报告目的是：(1) 审查包括顺铂和卡铂在内的铂类化合物和放疗引起的耳毒性；(2) 简要描述耳蜗病理生理学和与顺铂相关的听力损失的遗传学；(3) 解释化疗和放疗引起的听力损失的影响；(4) 提供有关评估和管理有治疗相关性听力损失风险的儿科患者的建议。作为一种辅助儿科医生进行评估的工具，调查问卷也包含其中。
